Recent developments in the diagnosis and management of severe sepsis

Chest

Volumn 132, Issue 6, 2007, Pages 1967-1976

  Wheeler, Arthur P ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ARDS; Sepsis; Septic shock; Severe sepsis

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; CORTICOTROPIN; FLUDROCORTISONE; GLUCOCORTICOID; GLUCOSE; HYDROCORTISONE; INTERLEUKIN 6; MINERALOCORTICOID;

ACUTE LUNG INJURY; ADRENAL INSUFFICIENCY; APACHE; ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; HEMODYNAMICS; HUMAN; INTENSIVE CARE UNIT; NONHUMAN; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RESUSCITATION; SEPSIS; SEPTIC SHOCK; TIDAL VOLUME;

EID: 37549024590     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.06-2535     Document Type: Article

References (98)

1. Marini JJ, Wheeler AP. Critical care medicine: the essentials. 2nd ed. Baltimore, MD: Williams and Wilkens, 1997
2. Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003; 348:683-694
3. Angus DC, Laterre PF, Helterbrand J, et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 2004; 32:2199-2206
4. Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006; 34:1996-2003
5. Gibot S, Cravoisy A, Kolopp-Sarda MN, et al. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med 2005; 33:792-796
6. Voves C, Wuillemin WA, Zeerleder S. International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients. Blood Coagul Fibrinolysis 2006; 17:445-451
7. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164:396-402
8. Shorr AF, Bernard GR, Dhainaut JF, et al. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Crit Care 2006; 10:R92
9. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250-1256
10. Padkin A, Goldfrad C, Brady AR, et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 2003; 31:2332-2338
11. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377
12. Levi M, van der Poll T. Coagulation in sepsis: all bugs bite equally. Crit Care 2004; 8:99-100
13. Kinasewitz GT, Yan SB, Basson B, et al. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism. Crit Care 2004; 8:R82-R90
14. Opal SM, Garber GE, LaRosa SP, et al. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 2003; 37:50-58
15. Dhainaut JF, Shorr AF, Macias WL, et al. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 2005; 33: 341-348
16. Estenssoro E, Gonzalez F, Laffaire E, et al. Shock on admission day is the best predictor of prolonged mechanical ventilation in the ICU. Chest 2005; 127:598-603
17. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554
18. Levy MM, Macias WL, Vincent JL, et al. Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med 2005; 33:2194-2201
19. Danai PA, Moss M, Mannino DM, et al. The epidemiology of sepsis in patients with malignancy. Chest 2006; 129:1432-1440
20. Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med 2006; 34:15-21
21. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34:552-554
22. Reinhart K, Vincent J-L, Ramsay G, et al. Data from the top ten enrolling countries contained in the PROGRESS registry demonstrates variations in treatment and high mortality rates [abstract]. Chest 2005; 128:377S
23. Nguyen HB, Rivers EP, Knoblich BP, et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med 2004; 32:1637-1642
24. Macias WL. Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 2004; 32:S223-S228
25. Sakr Y. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med 2004; 32:1825-1831
26. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003; 101:3765-3777
27. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150
28. Amaral A, Opal SM, Vincent JL. Coagulation in sepsis. Intensive Care Med 2004; 30:1032-1040
29. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe Lancet 2005; 366:1079-1084
30. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-2441
31. Warren DK, Zack JE, Mayfield JL, et al. The effect of an education program on the incidence of central venous catheter-associated bloodstream infection in a medical ICU. Chest 2004; 126:1612-1618
32. Berenholtz SM, Pronovost PJ, Lipsett PA, et al. Eliminating catheter-related bloodstream infections in the intensive care unit. Crit Care Med 2004; 32:2014-2020
33. Crnich CJ, Maki DG. Are antimicrobial-impregnated catheters effective? Don't throw out the baby with the bathwater. Clin Infect Dis 2004; 38:1287-1292
34. Baxter AD. Adherence to simple and effective measures reduces the incidence of ventilator-associated pneumonia. Can J Anaesth 2005; 52:535-541
35. Helman DL. Effect of standardized orders and provide education on head of bed positioning in mechanically ventilated patients. Crit Care Med 2003; 31:2285-2290
36. Koeman M, van der Ven AJ, Hak E, et al. Oral decontamination with chlorhexidine reduces the incidence of ventilator associated pneumonia. Am J Respir Crit Care Med 2006; 173:1348-1355
37. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873
38. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997; 336:912-918
39. Leibovici L, Shraga I, Drucker M, et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244:379-386
40. Kollef MH, Shennan G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-474
41. Harbarth S, Garbino J, Pugin J, et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115:529-535
42. Engorgen M. The effect of prompt physician visits on intensive care unit mortality and cost. Crit Care Med 2005; 33:727-732
43. Lebrovicki, Kang CI, Kim SH, et al. Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49:760-766
44. Lodise TP, McKinnon PS, Swiderski L, et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36:1418-1423
45. Honek PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164:637-644
46. Zaragoza R, Artero A, Camarena JJ, et al. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 2003; 9:412-418
47. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596
48. Micek ST, Heuring TJ, Hollands JM, et al. Optimizing antibiotic treatment for ventilator-associated pneumonia. Pharmacotherapy 2006; 26:204-213
49. The SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 22:2247-2256
50. Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients, N Engl J Med 1994; 330:1717-1722
51. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 1995; 333:1025-1032
52. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care: Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409-417
53. Jones AE, Kline JA. Use of goal-directed therapy for severe sepsis and septic shock in academic emergency departments Crit Care Med 2005; 33:1888-1889
54. Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury: National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. N Engl J Med 2006; 354:2564-2575
55. Wheeler AP, Bernard GR, Thompson BT, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury: National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. N Engl J Med 2006; 354:2213-2224
56. Rivers EP. Fluid-management strategies in acute lung injury: liberal, conservative, or both? N Engl J Med 2006; 354:2598-2600
57. Kellum JA, Decker JM. The use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001; 29:1526-1531
58. Mullner M, Urbanek B, Havel C, et al. Vasopressors for shock. Cochrane Database Syst Rev (database online). Issue 3, 2004
59. Sakr Y, Reinhart K, Vincent JL, et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med 2006; 34:589-597
60. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345:588-595
61. Dunser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003; 107:2313-2319
62. Acute Respiratory Distress Syndrome Network. Ventilation with low tidal volumes compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342:1301-1308
63. Eisner MD, Thompson T, Hudson LD, et al. Efficacy of low tidal volume ventilation in patients with different clinical risk factors for acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 164:231-236
64. Esteban A, Alia I, Gordo F, et al. Prospective randomized trial comparing pressure-controlled ventilation and volume-controlled ventilation in ARDS: for the Spanish Lung Failure Collaborative Group. Chest 2000; 117:1690-1696
65. Acute Respiratory Distress Syndrome Network. Tidal volume reduction in patients with acute lung injury when plateau pressures are not high. Am J Respir Crit Care Med 2005; 172:1241-1245
66. Sakr Y, Vincent JL, Reinhart K, et al. High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest 2005; 128:3098-3108
67. Gajic O, Dara SI, Mendez JL, et al. Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation. Crit Care Med 2004; 32:1817-1824
68. Kahn JM, Andersson L, Karir V, et al. Low tidal volume ventilation does not increase sedation use in patients with acute lung injury. Crit Care Med 2005; 33:766-771
69. Webb HH, Tierney DF. Experimental pulmonary edema due to intermittent positive pressure ventilation with high inflation pressures: protection by positive end-expiratory pressure. Am Rev Respir Dis 1974; 110:556-565
70. Tremblay L, Valenza F, Ribeiro SP, et al. Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. J Clin Invest 1997; 99:944-952
71. Brower RG, Lanken PN, MacIntyre N, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004; 351:327-336
72. Gattinoni L, Caironi P, Cressoni M, et al. Lung recruitment in patients with the acute respiratory distress syndrome. N Engl J Med 2006; 354:1775-1786
73. Annane D. Corticosteroids for severe sepsis and septic shock a systematic review and meta-analysis BMJ 2004; 329:480
74. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871
75. Siraux V, De Backer D, Yalavatti G, et al. Relative adrenal insufficiency in patients with septic shock: comparison of low-dose and conventional corticotropin tests. Crit Care Med 2005; 33:2479-2486
76. Hamrahian AH, Tawakalitu SO, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004; 350:1629-1638
77. Levy H, Laterre PF, Bates B, et al. Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated). Crit Care 2005; 9:R502-R507
78. Minneci PC, Deans KJ, Banks SM, et al. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004; 141:47-56
79. Annane D, Briegel J, Keh D, et al. Clinical equipoise remains for issues of adrenocorticotropic hormone administration, cortisol testing, and therapeutic use of hydrocortisone. Crit Care Med 2003; 31:2250-2251
80. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003; 78:1471-1478
81. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-1367
82. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354:449-461
83. Finney SJ, Zekveld C, Elia A, et al. Glucose control and mortality in critically ill patients. JAMA 2003; 290:2041-2047
84. Van den Berghe G, Wouters R, Weekers F, et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 2003; 31:359-366
85. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
86. Angus DC, Laterre PF, Helterbrand J, et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 2004; 32:2199-2206
87. Vincent JL, Angus DC, Artigas A, et al. Effects of Drotrecogin alfa activated on organ dysfunction in the prowess trial. Crit Care Med 2003; 31:834-840
88. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341
89. Kerr M. Drotrecogin alfa does not improve outcome in children with sepsis. Available at: http://www.medscape.com/viewarticle/521400. Accessed July 7, 2006
90. Vincent J-L, Light B, Wright T, et al. Drotrecogin alfa (Activated) treatment in severe sepsis form the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005; 33:2266-2277
91. Vincent J-L, O'Brien J Jr, Wheeler A, et al. Use of an integrated clinical trial database to evaluate the effect of timing of Drotrecogin alfa (activated) treatment in severe sepsis. Crit Care 2006; 10:R74
92. Frampton JE, Foster RH. Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis. Pharmacoeconomics 2004; 22:445-476
93. Angus DC, Linde-Zwirble WT, Clermont G, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003; 1:1-11
94. Shapiro NI, Howell MD, Talmor D, et al. Implementation and outcomes of the Multiple Urgent Sepsis Therapies (MUST) protocol. Crit Care Med 2006; 34:1025-1032
95. Trzeciak S, Dellinger RP, Abate NL, et al. Translating research to clinical practice: a 1-year experience with implementing early goal-directed therapy for septic shock in the emergency department. Chest 2006; 129:225-232
96. Sebat F, Johnson D, Musthafa AA, et al. A multidisciplinary community hospital program for early and rapid resuscitation of shock in nontrauma patients. Chest 2005; 127:1729-1743
97. Kortgen A, Niederprum P, Bauer M. Implementation of an evidence-based "standard operating procedure" and outcome in septic shock. Crit Care Med 2006; 34:943-949
98. Gao F, Melody T, Daniels DF, et al. The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: a prospective observational study. Crit Care 2005; 9:R764-R770